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The dopamine transporter (DAT) removes dopamine
from the extracellular milieu and is potently inhibited
by number of psychoactive drugs, including cocaine,
amphetamines, and methylphenidate (Ritalin). Multiple
lines of evidence demonstrate that protein kinase C
(PKC) down-regulates dopamine transport, primarily by
redistributing DAT from the plasma membrane to endo-
somal compartments, although the mechanisms facili-
tating transporter sequestration are not defined. Here,
we demonstrate that DAT constitutively internalizes
and recycles in rat pheochromocytoma (PC12) cells.
Temperature blockades demonstrated basal internaliza-
tion and reliance on recycling to maintain DAT cell sur-
face levels. In contrast, recycling blockade with bafilo-
mycin A1 significantly decreased transferrin receptor
(TfR) surface expression but had no effect on DAT sur-
face levels, suggesting that DAT and TfR traffic via dis-
tinct endosomal mechanisms. Kinetic analyses reveal
robust constitutive DAT cycling to and from the plasma
membrane, independent of transporter expression lev-
els. In contrast, phorbol ester-mediated PKC activation
accelerated DAT endocytosis and attenuated trans-
porter recycling in a manner sensitive to DAT expres-
sion levels. These data demonstrate constitutive DAT
trafficking and that PKC-mediated DAT sequestration is
achieved by a combination of accelerated internaliza-
tion and reduced recycling. Additionally, the differen-
tial sensitivity to expression level exhibited by constitu-
tive and regulated DAT trafficking suggests that these
two processes are mediated by independent cellular
mechanisms.
Dopaminergic neurotransmission is fundamental to a vari-
ety of central nervous system functions, including motor con-
trol (1, 2) and cognition (3). Aberrant DA1 neurotransmission is
implicated in Parkinson’s disease (4, 5) and schizophrenia (6,
7), the symptoms of which are ameliorated by increasing and
decreasing DA signaling, respectively. Once released into the
synapse, the primary mechanism limiting extracellular DA
concentrations is presynaptic re-uptake mediated by the
plasma membrane DAT. DAT belongs to the Na/Cl-depend-
ent transporter gene family (8, 9) and is potently inhibited by
the addictive psychostimulants cocaine and amphetamine (10),
making DAT a major psychostimulant target in the brain.
Indeed, cocaine and amphetamines neither raise extra-
cellular DA levels (11) nor produce hyperlocomotion (12, 13) in
DAT/ mice. A recent report also implicates DAT in non-
vesicular DA release in the substantia nigra somatodendritic
region (14). Hence the number of functional DATs present on
the plasma membrane directly impacts dopaminergic signaling
and psychostimulant efficacy.
Although once considered static resident plasma membrane
proteins, a growing body of evidence demonstrates that DAT
surface expression is highly dynamic. The best documented
example is through acute PKC activation, which down-regu-
lates DAT and its homologues by decreasing their plasma
membrane presentation (8, 15, 16). Moreover, DAT surface
presentation is acutely sensitive to the psychostimulants am-
phetamine (17) and cocaine (18, 19), which decrease and in-
crease DAT surface levels, respectively. Taken together, these
findings suggest that membrane trafficking is a fundamental
mechanism governing DAT homeostasis and regulation. This
hypothesis is further supported by evidence that the dominant
negative dynamin mutant K44A blocks both PKC (20)- and
amphetamine-mediated (17) DAT sequestration, suggesting
that clathrin-mediated endocytosis is required for many trans-
porter regulatory processes.
Our previous report (21) demonstrated that DAT basally
distributes evenly between the plasma membrane and endoso-
mal compartments, and that surface DAT translocates to the
recycling endosome in response to PKC activation. A lingering
question arising from these studies is whether PKC-induced
DAT losses from the plasma membrane occur by accelerating
DAT internalization, attenuating DAT recycling, or a combina-
tion of both. Further, it is unknown whether DAT significantly
traffics under basal conditions. Here, we tested the hypotheses
that DAT constitutively cycles to and from the plasma mem-
brane and that PKC activation modulates already existent
DAT trafficking. Our results demonstrate surprisingly robust
constitutive DAT trafficking, which is modulated in response to
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PKC activation, suggesting that DAT surface expression is
highly dynamic even under basal conditions.
EXPERIMENTAL PROCEDURES
Materials—Bafilomycin A1 and GBR12909 were from Tocris-Cook-
son (Ellisville, MO). Rat monoclonal DAT antibody and all horseradish
peroxidase-conjugated secondary antibodies were from Chemicon
(Temecula, CA). Mouse anti-TfR antibody was from Zymed Laborato-
ries Inc. (South San Francisco, CA). Rabbit anti-rab5A antibody and
mouse anti-rab11 and anti-EEA1 antibodies were from Santa Cruz
Biotechnology (Santa Cruz, CA). All other reagents were of the high
possible quality and were obtained from Sigma unless otherwise noted.
Cell Culture and Uptake Assays—PC12 cells stably expressing the
human DAT (DAT-PC12) were cultured at 37 °C, 10% CO2 as described
previously (21). The cell line 4.27.37 was used for the majority of
experiments, and cell lines 5.11.18 and 5.11.33 were also used where
specified. For uptake, cells were plated in triplicate on poly-D-lysine-
coated 24-well plates 1 day prior to performing the assays. Cells were
rinsed and preincubated in KRH buffer (120 mM NaCl, 4.7 mM KCl, 2.2
mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, 0.18% glucose, 10 mM
HEPES, pH 7.4) at either 18 or 37 °C for 30 min in the presence of 100
nM desipramine to block endogenous NET activity. Cells were shifted to
18 °C for 2 min, and uptake was initiated with 1.0 M [3H]DA (3,4-[ring-
2,5,6,-3H]DA, PerkinElmer Life Sciences) containing 105 M pargyline
and 105 M ascorbic acid. Assays proceeded for 10 min (18 °C) and were
terminated by rapidly washing cells with ice-cold KRH buffer. Cells
were solubilized in 1% SDS, and accumulated radioactivity was deter-
mined by liquid scintillation counting. Nonspecific uptake was defined
in the presence of 100 nM desipramine and 10 M GBR12909. Data
analysis was performed using Microsoft Excel and KaleidaGraph
(Synergy Software). Statistical analysis was performed using Instat
(GraphPad Software).
Cell Surface Biotinylation—DAT-PC12 cells, grown to 75% conflu-
ency on poly-D-lysine-coated six-well plates, for the designated times
and temperatures were washed with and incubated in PBS2/B/g (PBS
supplemented with 1.0 mM MgCl2, 0.1 mM CaCl2, 0.2% bovine serum
albumin, 0.18% glucose). Plasma membrane proteins were biotinylated
with sulfo-NHS-SS-biotin essentially as described previously (21). Cells
were lysed in radioimmune precipitation buffer (10 mM Tris, pH 7.4, 150
mM NaCl, 1.0 mM EDTA, 0.1% SDS, 1.0% Triton X-100, 1.0% sodium
deoxycholate) containing protease inhibitors (1.0 mM phenylmethylsul-
fonyl fluoride, and 1.0 g/ml each leupeptin, aprotinin, and pepstatin),
and cellular debris was removed by centrifugation. Biotinylated and
nonbiotinylated proteins from equivalent amounts of total cellular pro-
tein were separated by streptavidin pull-down, and the resulting
eluents and supernatants were assessed by immunoblot as described
previously (21). Nonsaturating, immunoreactive bands were quanti-
tated either by scanning densitometry or with a CCD camera gel doc-
umentation system (ChemiDoc, Bio-Rad), and nonsaturating bands
were quantitated with Quantity One software (Bio-Rad).
Internalization Assay—DAT-PC12 cells were plated on duplicate
poly-D-lysine-coated six-well plates and underwent biotinylation with
2.5 mg/ml sulfo-NHS-SS-biotin as described. Following biotinylation,
one set of cells was washed with PBS2 (3  2 ml) and kept at 4 °C to
determine the total initial surface DAT and strip efficiencies. To initiate
endocytosis, cells in the duplicate plate were washed repeatedly with
prewarmed (37 °C) PBS2/B/g containing either 1 M PMA or vehicle
and incubated with the same solutions for 10 min at 37 °C. To assure
rapid temperature shift to 37 °C, temperatures were monitored in rep-
resentative wells and were found to be completely shifted to 37 °C in
less than 2 min. Endocytosis was rapidly stopped by placing plates
immediately in a slushy ice bath and washing 3  2 ml with ice-cold
PBS2. Residual cell surface biotin was stripped by incubating cells
twice for 25 min with freshly prepared 50 mM MesNa in NT buffer (150
mM NaCl, 1 mM EDTA, 0.2% bovine serum albumin, 20 mM Tris, pH
8.6). Strip efficiency was determined for each experiment on biotinyl-
ated cells kept in parallel at 4 °C and averaged 95%. Cells were lysed
in radioimmune precipitation buffer with protease inhibitors, biotinyl-
ated proteins were separated from nonbiotinylated proteins by strepta-
vidin pull-down from equivalent amounts of cellular protein, and sam-
ples were analyzed by SDS-PAGE and immunoblot as described above.
Immunoreactive bands were detected with a cooled, CCD camera
(ChemiDoc system, Bio-Rad), and bands in the linear range of detection
were quantitated using Quantity One software (Bio-Rad). Relative DAT
endocytic rates were calculated as the percent DAT internalized com-
pared with total initial DAT surface pool.
Biotinylation of Recycling DAT Pool—DAT-PC12 cells plated on poly-
D-lysine-coated six-well plates were washed and preincubated in pre-
warmed PBS2 for 20 min at 37 °C. Cells were incubated either three
times for 15 min (for 45-min biotinylation) or three times for 10 min (for
30-min biotinylation) with 1.0 mg/ml sulfo-NHS-SS-biotin in PBS2 at
37 °C. Following glycine quench, cells were lysed, and biotinylated
proteins were separated from nonbiotinylated proteins by strepta-
vidin pull-down and analyzed by SDS-PAGE and immunoblot as
described above.
RESULTS
In our previous study of DAT-transfected PC12 cells (21),
under steady state conditions we observed a sizeable intracel-
lular DAT pool that localized to recycling endosomes, suggest-
ing that DAT may be subject to considerable basal trafficking.
In the present study, we tested the hypothesis that DAT con-
stitutively traffics from and back to the plasma membrane and
that DAT redistribution in response to PKC activation results
from altering existing DAT trafficking kinetics.
Constitutive DAT Trafficking—To determine whether DAT
undergoes constitutive membrane trafficking, we globally
blocked endocytic recycling and assessed the resultant effects
on DAT function and surface expression. First, we subjected
DAT-PC12 cells to an 18 °C blockade, which is temperature-
permissive to endocytosis but significantly attenuates exit from
the early endosome (22–25). Thus, if DAT constitutively inter-
nalizes and recycles, we would expect DAT surface presenta-
tion to decrease during 18 °C incubations. A 30-min incubation
at 18 °C reduced DA uptake by 52.7  10.6% when compared
with cells preincubated in parallel at 37 °C (Fig. 1A). Cell
surface biotinylation revealed that the 18 °C treatment de-
creased DAT surface expression by 38.8  6.1% as compared
with control cells incubated in parallel at 37 °C (Fig. 1B), with
no losses in total DAT (data not shown). DAT surface losses
FIG. 1. 18 °C recycling blockade decreases DA transport and
DAT surface expression in DAT-PC12 cells. A, DA uptake assay of
DAT-PC12 cells preincubated at 37 °C (filled bar) or 18 °C (open bar) for
30 min. Data are expressed as % control uptake  S.E. *, p  0.005
(Student’s t test, n  4). B, steady state cell surface biotinylation of
DAT-PC12 cells. Inset, representative immunoblot showing surface
DAT and TfR after incubation at 37 or 18 °C. Bar graph, averaged data
expressed as % loss of 37 °C cell surface pool  S.E. (n  3, DAT;
n  2, TfR).
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were not significantly different from those observed for TfR
(Fig. 1B, 52.6  7.9% of control), a protein that undergoes
robust constitutive cycling.
DAT surface losses following the 18 °C incubation suggest that
DAT constitutively internalizes under steady state conditions
and that recycling is required to maintain steady state DAT
surface levels. However, because 18 °C also attenuates exit from
the trans-Golgi network, loss of surface DAT at 18 °C may simply
reflect normal DAT turnover in the absence of biosynthetic re-
plenishment. To rule out the contribution of newly synthesized
DAT to the cell surface pool, we examined total and surface DAT
while protein synthesis was blocked with cycloheximide. Cyclo-
heximide treatment (10 M) inhibited [35S]methionine/cysteine
incorporation into total cellular protein by 90% over a time
span of 3 h but had no significant effect on either DAT surface
levels or total DAT levels (ANOVA, p  0.28, n  2; data not
shown). These results demonstrate that the biosynthetic contri-
bution of DAT to the cell surface pool is not significant in the time
frames in which our experiments were performed.
To further examine the role of recycling in maintaining DAT
surface levels, we blocked constitutive recycling with the vac-
uolar ATPase inhibitor bafilomycin A1, which blocks TfR recy-
cling and reduces TfR surface expression (26). Bafilomycin
treatment (0.5 M) for 30 min reduced TfR plasma membrane
expression to 60.6  6.6% of that observed for vehicle-treated
cells (Fig. 2), which was not significantly different from the
effect of bafilomycin on TfR surface expression in nontrans-
fected PC12 cells (63.2  6.8%; data not shown). Surprisingly,
DAT exhibited a trend toward increased surface expression in
response to bafilomycin A1 treatment (117  8.0% of vehicle,
n  4). Taken together with our 18 °C temperature block re-
sults, these data demonstrate that DAT constitutively traffics
but suggest that DAT trafficking is mechanistically distinct
from that of TfR.
PKC-modulated DAT Trafficking—To test whether intracel-
lular DAT accumulation in response to PKC activation is due to
increased DAT internalization, we examined DAT endocytosis
directly. As endocytic rates for rapidly internalizing proteins
are linear for 10–15 min post-initial internalization (27–29),
we used a 10-min internalization assay to determine relative
DAT endocytic rates in DAT-PC12 cells (clonal line 4.27.37). As
seen in Fig. 3, DAT exhibited robust basal internalization as-
sessed over a time span of 10 min (27.29 3.4%, n 6), directly
demonstrating constitutive DAT endocytosis. Phorbol ester-
mediated PKC activation induced a significant increase in the
%DAT internalized (43.9  3.2% n  12), whereas vehicle
treatment had no significant effect on DAT internalization
(38.9  6.1%; see Table I). The lack of difference in DAT
internalization was not because of a lag in PMA efficacy, as we
FIG. 2. Bafilomycin reduces the surface expression of TfR but
not DAT in DAT-PC12 cells. A, representative immunoblot of cell
surface DAT and TfR following 30-min treatment with vehicle or 0.5 M
bafilomycin A1. B, quantitation of DAT and TfR surface levels following
treatment with vehicle (open bars) versus 0.5 M bafilomycin A1 (filled
bars). Data are expressed as % vehicle surface pool  S.E. *, p  0.005
compared with vehicle-treated cells (Student’s t test, n  4).
FIG. 3. Relative DAT internalization rates are sensitive to PKC
activation and expression level. A, representative immunoblot
showing total cell surface DAT labeled at 0 °C (total), MesNa strip of
0 °C biotinylated cells (strip), and 10	 internalized DAT 1 M PMA. B,
DAT internalization was assessed at 37 °C in untreated (open bars)
versus 1 M PMA-treated (filled bars) DAT-PC12 cell lines. Data are
expressed as % total surface DAT internalized in 10 min  S.E. (n 
2–11). *, p  0.01 compared with vehicle-treated cells (Student’s t test,
n  5–12). Inset, immunoblot of DAT expression in three stably trans-
fected DAT-PC12 cell lines. Equivalent amounts of total cellular protein
were loaded. C, time course of PMA effect on DA transport. Data are
expressed as % specific DA uptake  S.E. *, p  0.01 (ANOVA with
Dunnett’s post hoc analysis, n  2).
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detected significant losses in [3H]DA uptake as early as 1 min
after PMA addition (Fig. 3C).
Given that our stable cell line was derived from a single
clone, we asked whether DAT expression levels in our stable
PC12 cell line might potentially influence constitutive and
regulated DAT endocytosis. To test this possibility, we evalu-
ated DAT trafficking in two other clonal DAT-PC12 cell lines
that express 5.8 1.8-fold more (5.11.18 cells, n 3) and 7.8
1.6-fold less (5.11.33 cells, n  5) DAT than the 4.27.37 DAT-
PC12 cell line, as assessed by quantitative immunoblot (Fig 3B,
inset). Cell surface biotinylation revealed that DAT expression
level had no effect on the percent total DAT expressed at the
plasma membrane (Table I). Similarly, 10-min internalization
studies demonstrated that constitutive DAT internalization
occurs at the same rate, independently of DAT expression
levels (Table I). In cells with the lowest DAT expression level
(5.11.33), treatment with 1 M PMA increased DAT endocytosis
from 30.3  4.9% (basal, n  6) to 51.8  3.3% (PMA, n  5),
consistent with our findings in the moderately expressing
4.27.37 cell line (see above). In striking contrast, cells with high
DAT expression levels (5.11.18 cells) exhibited comparable basal
DAT endocytosis (25.7  5.2%, n  5) that did not significantly
change in response to PKC activation (Fig. 3B, 36.6  5.6%).
Taken together, these results demonstrate that DAT constitu-
tively internalizes in a manner that is insensitive to the DAT
expression level and that PKC activation enhances DAT endocy-
tosis in a manner sensitive to the DAT expression level.
Although our results demonstrating loss of surface DAT dur-
ing the 18 °C temperature block strongly suggest that DAT
constitutively recycles, direct demonstration of DAT recycling
has not been achieved to date. To further investigate DAT
recycling, we performed biotinylation at 37 °C with the cell-
impermeant biotinylation reagent sulfo-NHS-SS-biotin. We
reasoned that if DAT constitutively traffics to and from the
plasma membrane, then biotinylation under trafficking-per-
missive conditions (37 °C) should significantly increase the
amount of biotinylated DAT as compared with biotinylation
performed under trafficking-restrictive conditions (0 °C). Biotin-
ylation at 37 °C for 45 min was sufficient to biotinylate essen-
tially the entire DAT and TfR pools in 4.27.37 DAT-PC12 cells
(Fig. 4A). Under these conditions, the early endosomal marker
rab5A was not biotinylated nor was there an increase in
sodium/potassium ATPase biotinylation at 37 versus 0 °C
(not shown), demonstrating the specificity of the 37 °C bioti-
nylation for constitutively trafficking proteins. We next per-
formed 37 °C biotinylation to investigate the effect of acute
PKC activation on DAT recycling in the three DAT-PC12 cell
lines. Both DAT and TfR robustly recycled to the plasma
membrane independently of DAT expression level (Fig. 4, C
and D), and PKC activation had no effect on TfR recycling
(Fig. 4D). However, PMA treatment significantly reduced
DAT recycling in low and moderately expressing DAT-PC12
cells, whereas DAT recycling was not reduced in the high
expressing cell line. These results suggest that DAT consti-
tutively recycles in a manner independent of expression level
and that PKC activation slows DAT recycling back to the
plasma membrane.
FIG. 4. DAT constitutively recycles and PKC decreases DAT
recycling rates. A, biotinylation for 45 min at 4 and 37 °C. Biotinyl-
ated (B) and nonbiotinylated (NB) proteins were separated by strepta-
vidin pull-down and assessed by immunoblot for DAT, TfR, and the
early endosomal marker rab5A. Similar results were obtained in three
independent experiments. B, DAT-PC12 cells were biotinylated for 30
min at either 0 or 37 °C in the presence of vehicle or 1 M PMA.
Biotinylated and nonbiotinylated proteins were separated by strepta-
vidin pull-down. A representative blot is shown. C, averaged DAT
recycling data from 0 °C (hatched bars) versus 37 °C biotinylation in the
presence of either vehicle (open bars) or 1 M PMA (filled bars). Data
are expressed as % maximal biotinylated protein  S.E. for each cell
line. *, p  0.001 compared with 0 °C biotinylation (ANOVA with
Bonferroni multiple comparisons test, n  5–8); **, p  0.05 compared
with 37 °C vehicle treatment (ANOVA with Bonferroni multiple com-
parisons test, n  5–8). D, averaged TfR recycling data from 0 °C
(hatched bars) versus 37 °C biotinylation in the presence of either ve-
hicle (open bars) or 1 M PMA (filled bars). Data are expressed as %
maximal biotinylated protein  S.E. *, p  0.01 compared with 0 °C
biotinylation (ANOVA with Bonferroni multiple comparisons test,
n  2–8).
TABLE I
Effect of DAT expression level on DAT trafficking in stably transfected PC12 cell lines
Data are expressed as mean  S.E. Numbers (n) in parentheses are the number of independent experiments.
DAT attribute evaluated
DAT-PC12 cell line
5.11.33 (n) 4.27.37 (n) 5.11.18 (n)
Relative DAT expression level 0.13 1.00 5.85
Surface expression (% total DAT) 39.5  2.4 (7) 43.3  2.5 (8) 47.1  1.8 (4)
Internalization (% internalized/10 min)
Basala 30.3  4.9 (6) 27.2  3.4 (6) 25.7  5.2 (5)
Vehiclea 25.0  2.0 (2) 38.9  6.1 (7) 12.6  0.4 (2)
1 M PMA 51.8  3.3b (5) 43.9  3.2b (12) 36.6  5.6 (6)
Recycling (% biotinylation, 37 °C, 30 min)
Vehiclea 72.7  3.7 (6) 74.5  3.4 (8) 80.6  4.0 (5)
1 M PMA 60.0  5.1c (5) 59.7  2.9c (7) 77.7  5.3 (5)
a No significant difference among cell lines, ANOVA (p  0.05).
b Significantly different from basal, Student’s t test (p  0.01).
c Significantly different from vehicle, Student’s t test (p  0.02).
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DISCUSSION
Recent reports indicate that membrane trafficking plays a
pivotal role in several forms of central nervous system plastic-
ity (30–33). Despite previous results demonstrating that mem-
brane trafficking mediates PKC-induced DAT down-regulation
(20, 21), the mechanisms underlying these regulatory events
are unknown. Here, we demonstrate that DAT robustly inter-
nalizes and recycles to the plasma membrane in PC12 cells and
that PKC-induced DAT sequestration is achieved by a combi-
nation of increased DAT internalization and decreased DAT
recycling. Similar PKC effects on both internalization and re-
cycling have recently been described for E-cadherin (34). Mod-
ulation of recycling rates is a mechanism known to occur for
other neuronal proteins, including transporters. For exam-
ple,-aminobutyric acid receptorA (35) and neuronal Na
/H
exchanger (36) constitutively traffic but are retained intracel-
lularly by attenuating recycling in response to PKC activation
and phosphatidylinositol 3-kinase inhibition, respectively. Al-
though the results in any expression system must be consid-
ered carefully, it is likely that DAT trafficking in PC12 cells
reflects neuronal DAT trafficking, as many neuronal proteins
traffic faithfully in PC12 cells as they do in neurons, including
the m4 muscarinic receptor (37–39), the neuronal Na/H ex-
changer (40), and the nerve growth factor receptor TrKA (41).
Moreover, our findings on constitutive DAT trafficking are
consistent with recent reports demonstrating that GAT1 inter-
nalizes and recycles rapidly both in hippocampal neurons (42)
and heterologous expression systems (43), suggesting that
transporter trafficking may be a fundamental process occur-
ring across the GAT1/NET gene family.
Many plasma membrane proteins are static in the plasma
membrane but internalize in response to activated cellular
signaling. For example, G-protein-coupled receptors exhibit
very little basal endocytosis (44, 45) but rapidly internalize
during agonist-induced desensitization (46, 47). In contrast,
proteins such as TfR (48), furin (49), and -aminobutyric acid
receptorA (35) are constitutively trafficked and can be regu-
lated at multiple endocytic stages. To examine whether DAT
constitutively traffics, we imposed two mechanistically inde-
pendent recycling blockades on DAT-PC12 cells: first, an 18 °C
temperature block and, second, treatment with the antibiotic
bafilomycin A1. We observed significant losses in both DA
transport and DAT surface expression when DAT-PC12 cells
were incubated at 18 °C for 30 min (Fig. 1). Interestingly, DAT
losses from the cell surface were not significantly different from
those observed for TfR (Fig. 1B), a protein that undergoes
constitutive endocytosis at a rate of 10%/min (48), suggesting
that basal DAT internalization rates may approach those of
TfR. DAT losses from the plasma membrane were not due to
blocking the exit of newly synthesized DAT from the trans-
Golgi network, as cycloheximide treatment did not alter either
DAT surface expression or total DAT levels in a 3-h time frame,
consistent with results from Daniels and Amara (20) examin-
ing the basal stability of green fluorescent protein-tagged DAT
in cycloheximide-treated Madin-Darby canine kidney cells.
Therefore, DAT surface losses at 18 °C reflect robust basal DAT
endocytosis, supporting the hypothesis that constitutive recy-
cling is necessary to maintain steady state DAT surface levels.
An acidic endosomal lumen is necessary for most proteins to
progress past the early endosome. Bafilomycin potently inhib-
its the vacuolar ATPase, thereby raising the endosomal pH and
arresting endocytic trafficking (50, 51). Indeed, A 30-min
bafilomycin treatment significantly reduced TfR surface ex-
pression in both PC12 and DAT-PC12 cells (Fig. 2), consistent
with the findings of Presley et al. (26). Surprisingly, we ob-
served a trend toward increased DAT surface expression fol-
lowing bafilomycin treatment, suggesting that early endocytic
trafficking of DAT and TfR are mechanistically distinct. DAT
may reside in a subpopulation of early endosomes that is rel-
atively insensitive to bafilomycin and/or pH changes such as
reported for cellubrevin (52). Alternatively, DAT may be intrin-
sically less dependent upon pH for endosomal sorting. Inter-
estingly, Chinni and Shisheva (53) observed bafilomycin-in-
duced GLUT4 translocation to the plasma membrane, similar
to the actions of insulin but downstream of phosphatidylinosi-
tol 3-kinase activity. Both DAT (54) and NET (55) are similar to
GLUT4, in that they exhibit phosphatidylinositol 3-kinase-de-
pendent, insulin-induced increases in surface expression.
Given our results that bafilomycin does not decrease, and may
increase, DAT surface expression, it is tempting to speculate
that DAT and GLUT4 recycling may share common mecha-
nisms. Future studies aimed at elucidating the mechanisms
underlying DAT endocytic trafficking should be illuminating in
this regard.
Given our results that DAT constitutively internalizes and
recycles, we investigated whether PKC increases DAT inter-
nalization, decreases DAT recycling or both. DAT internalized
basally at 30% in 10 min, which translates into a plasma
membrane t1⁄2  13 min. These results, consistent with our
findings demonstrating 18 °C-induced DAT surface losses, di-
rectly confirm basal DAT internalization. PKC activation did
not significantly change the endocytic rate of DAT when DAT
was expressed at high levels but markedly increased DAT
endocytosis when DAT was expressed at low and moderate
levels (Fig. 3B). Interestingly, although regulated DAT traffick-
ing was sensitive to DAT expression levels, constitutive DAT
trafficking was essentially identical across the three cell lines
used, representing a 45-fold range in DAT protein levels.
These results raise the possibility that constitutive and regu-
lated DAT trafficking occur via distinct cellular mechanisms,
consistent with the differential trafficking saturation levels
observed for other membrane proteins. For example, -adre-
nergic receptor overexpression saturates its trafficking but not
that of the TfR (56). Similarly, TfR, low-density lipoprotein
receptor and epidermal growth factor receptor expression at
levels sufficient to saturate endocytosis for an individual recep-
tor do not saturate the endocytic capacity of another receptor,
consistent with the concept of distinct endocytic pathways
and/or cofactors for these three receptors (57).
We previously demonstrated DAT enrichment in the TfR-
positive recycling endosomes under basal conditions and DAT
translocation to recycling endosomes during PKC stimulation
(21). Basal DAT enrichment in recycling endosomes strongly
suggests that DAT constitutively recycles to the cell surface. To
directly test whether DAT recycles, we compared DAT biotin-
ylation at 37 versus 0 °C using the cell-impermeant biotinyla-
tion reagent sulfo-NHS-SS-biotin. When DAT-PC12 cells were
FIG. 5. Model for constitutive and PKC-regulated DAT traf-
ficking. Dynamic DAT trafficking is a rheostat that fine-tunes DA
signaling. Under basal conditions DAT continually cycles through the
endocytic pathway. Upon PKC activation, DAT internalization is accel-
erated, and DAT recycling back to the cell surface is attenuated. Thus,
DAT accumulates in recycling endosomes, and DAT surface pools
are depleted.
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biotinylated at trafficking-restrictive temperatures (0 °C), we
consistently observed 43.3  2.5% of total DAT on the cell
surface (Table I). We predicted that if we biotinylated DAT-
PC12 cells under trafficking-permissive conditions (37 °C), re-
cycling proteins would gain access to the biotinylation reagent
as they reached the plasma membrane and we would observe
significant increases in the percent total biotinylation. Indeed,
we observed complete biotinylation of both TfR and DAT after
45 min at 37 °C (Fig. 4A), suggesting that DAT recycles to the
plasma membrane and does so in a time frame comparable
with that of the TfR. Biotinylation at 37 °C was restricted to
constitutively trafficking proteins, as the early endosomal
marker rab5A was not biotinylated at 37 °C (Fig. 4A) nor was
Na/K ATPase biotinylation increased (data not shown).
Our results demonstrating DAT recycling differ from those of
Daniels and Amara (20), who detected lysosomal degradation of
green fluorescent protein-tagged DAT during phorbol ester-
mediated PKC stimulation. These differences likely reflect ei-
ther PMA treatment times (30 min versus 1–4 h), the cell type
in which DAT was expressed (PC12 versus Madin-Darby canine
kidney cells), or the DAT form studied (wild type versus green
fluorescent protein-tagged). In striking contrast, when DAT-
PC12 cells were biotinylated at 37 °C for 30 min in the presence
of 1 M PMA, DAT biotinylation significantly decreased as
compared with vehicle-treated cells in low and moderate ex-
pression levels with no loss of total DAT. TfR recycling was
unaffected by PMA, suggesting that PMA does not have pleio-
tropic effects on membrane trafficking. Although we cannot
completely rule out the possibility that DAT exit rates from the
early endosome are not affected by PKC, our results suggest
that decreased DAT recycling causes a “back-up” of DAT in the
recycling endosome, consistent with our previous results de-
scribing PKC-mediated DAT translocation to recycling endo-
somes (21) (see model in Fig. 5). Interestingly, the altered
trafficking rates we detected do not completely account for the
rate at which DA transport activity is lost (Fig. 3C), suggesting
that PKC may also intrinsically inactivate DAT in addition to
altering DAT trafficking kinetics. Although we cannot com-
pletely rule out the possibility that DAT trafficking and activity
may be modulated by other signaling molecules stimulated by
the phorbol ester treatment, our previous work (21) and reports
from others (58–61) suggest that phorbol ester-mediated DAT
down-regulation occurs primarily via PKC activation. Future
studies examining endocytic-defective DAT point mutants
should distinguish between intrinsic and trafficking-mediated
DAT inactivation mechanisms.
What are the molecular factors governing constitutive DAT
trafficking? The DAT primary amino acid sequence codes for
several candidate dileucine motifs with potential to drive DAT
endocytosis. However, the specific DAT endocytic motif is not
defined currently. Phosphorylation is also linked to DAT traf-
ficking, as both PKC activation and protein phosphatase inhi-
bition increase DAT phosphorylation levels (59, 60). Proteolytic
digestion (62) and truncation approaches (63) demonstrate that
PKC increases in DAT phosphorylation are targeted to DAT
N-terminal domains, whereas site-directed mutagenesis sug-
gests that more distal residues are required for PKC mediated
DAT phosphorylation (64). However, PKC-induced DAT se-
questration still occurs in the absence of increased DAT phos-
phorylation, suggesting complex relationships among DAT
trafficking, phosphorylation, and regulation. Recent evidence
supports the hypothesis that transporter protein-protein inter-
actions are prominent in transporter trafficking and function.
For example, syntaxin 1A modulates GAT1 (65, 66), NET (67),
and SERT (68) trafficking and intrinsic activity. Additionally,
DAT, SERT, and NET exist in regulated complexes with pro-
tein phosphatases (69), and DAT complexes containing the
PDZ-binding protein PICK1 (70) and the adaptor protein Hic-5
(71) have been observed in neurons and expression systems.
Why would neurons expend energy to constantly cycle trans-
porters? Constitutive trafficking, perhaps best described for
the ionotropic glutamate receptors in dendritic spines (31, 72,
73), is emerging as a mechanism employed by neurons to prime
key signaling proteins for rapid redistribution. Likewise, trans-
porters play a key role in synaptic strength and are likely to
require a dynamically primed environment. Rather than re-
maining static and waiting for input to initiate trafficking,
constitutive DAT cycling operates much like a rheostat, capa-
ble of quickly and efficiently fine-tuning DA neurotransmission
(for model, see Fig. 5).
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